By Kelly Cloonan
Dyne Therapeutics named Erick Lucera as chief financial officer, effective March 31, adding an industry veteran of more than three decades to the biotechnology company.
Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at Aveo Pharmaceuticals and Valeritas Holdings.
Lucera will receive an annual base salary of $520,000 and will be eligible for an annual incentive bonus of up to 40% of his annualized base salary for each fiscal year, according to a filing with the Securities and Exchange Commission.
Editas promoted Amy Parison, senior vice president of finance, to succeed Lucera as CFO, effective March 28.
Parison, 39, will receive an annual base salary of $415,000 and will be eligible for an annual target bonus equal to 40% of her base salary.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 20, 2025 17:14 ET (21:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。